# A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis

> **NCT03972306** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 134 (actual)

## Conditions studied

- Multiple Sclerosis (MS)

## Interventions

- **DRUG:** Ocrelizumab
- **DRUG:** Ocrelizumab
- **DRUG:** rHuPH20

## Key facts

- **NCT ID:** NCT03972306
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-12
- **Primary completion:** 2025-06-03
- **Final completion:** 2025-06-03
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03972306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03972306, "A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03972306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*